LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer.

Yi Zeng; Yong Feng SI; Gui Ping Lan; Zhan Wang; Ling Zhou; Min Zhong Tang; O Brien SJ; Jiao Lan; Xiang Yang Zhou; Yong Li Wang; Juan Tang; Zhi Xiang Zhou; Hai Jun DU; Hui Lin

Return

LMP2-DC Vaccine Elicits Specific EBV-LMP2 Response to Effectively Improve Immunotherapy in Patients with Nasopharyngeal Cancer.

Author: Yi ZENG ^{1
,

2} ; Yong Feng SI ³ ; Gui Ping LAN ³ ; Zhan WANG ⁴ ; Ling ZHOU ⁴ ; Min Zhong TANG ⁵ ; O Brien SJ ⁶ ; Jiao LAN ³ ; Xiang Yang ZHOU ³ ; Yong Li WANG ³ ; Juan TANG ³ ; Zhi Xiang ZHOU ² ; Hai Jun DU ⁴ ; Hui LIN ³
Author Information

1. State Key Laboratory for Infectious Disease Prevention and Control, National Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
2. College of Life Science and Bioengineering, Beijing University of Technology, Beijing 100124, China.
3. People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China.
4. State Key Laboratory for Infectious Disease Prevention and Control, National Institute of Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China.
5. Cancer center, Wuzhou Red Cross Hospital, Wuzhou 543002, Guangxi, China.
6. Guy Harvey Oceanographic Center, Halmos College of Natural Sciences and Oceanography, Nova Southeastern University, Florida 33004, USA.
Publication Type:Journal Article
Keywords: Immunotherapy; LMP2- DCs; Nasopharyngeal carcinoma
MeSH: Adult; Aged; Cancer Vaccines/therapeutic use*; China; Dendritic Cells/immunology*; Female; Humans; Immunotherapy/methods*; Injections, Intradermal; Male; Middle Aged; Nasopharyngeal Carcinoma/therapy*; Nasopharyngeal Neoplasms/therapy*; T-Lymphocytes, Cytotoxic/immunology*; Viral Matrix Proteins/therapeutic use*; Young Adult
From: Biomedical and Environmental Sciences 2020;33(11):849-856
CountryChina
Language:English
Abstract: Objective:To evaluate the safety and effectiveness of a vaccine based on latent membrane protein 2 (LMP2) modified dendritic cells (DCs) that boosts specific responses of cytotoxic T lymphocytes (CTLs) to LMP2 before and after intradermal injection in patients with nasopharyngeal carcinoma (NPC).
Methods:DCs were derived from peripheral blood monocytes of patients with NPC. We prepared LMP2-DCs infected by recombinant adenovirus vector expressing LMP2 (rAd-LMP2). NPC patients were immunized with 2 × 10
Results:We demonstrated that DCs derived from monocytes displayed typical DC morphologies; the expression of LMP2 in the LMP2-DCs vaccine was confirmed by immunocytochemical assay. Twenty-nine patients with NPC were enrolled in this clinical trial. The LMP2-DCs vaccine was well tolerated in all of the patients. Boosted responses to LMP2 peptide sub-pools were observed in 18 of the 29 patients with NPC. The follow-up data of 29 immunized patients from April, 2010 to April 2015 indicated a five-year survival rate of 94.4% in responders and 45.5% in non-responders.
Conclusion:In this pilot study, we demonstrated that the LMP2-DCs vaccine is safe and effective in patients with NPC. Specific CTLs responses to LMP2 play a certain role in controlling and preventing the recurrence and metastasis of NPC, which warrants further clinical testing.